Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges
Identifieur interne : 001D43 ( Main/Exploration ); précédent : 001D42; suivant : 001D44Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges
Auteurs : Anette Schrag [Royaume-Uni] ; Ludwig Schelosky [Allemagne] ; Udo Scholz [Allemagne] ; Werner Poewe [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-03.
English descriptors
- KwdEn :
Abstract
We investigated the effect of an anticholinergic (biperiden) and a dopamine agonist (apomorphine) on tremor, rigidity, and akinesia in patients with idiopathic Parkinson's disease. In a standardized, crossover study design 17 patients received single‐dose challenges of 5 mg biperiden intravenously and a previously determined dose of apomorphine subcutaneously on 2 consecutive days. Resting (RT), postural (PT), and action tremor (AT) were assessed using spectral analysis of accelerometer data, and Unified Parkinson's Disease Rating Scale (UPDRS) scores for rigidity and akinesia were determined before and after administration of the study drug. Both single‐dose challenges significantly reduced the amplitude of RT, PT, and AT, but only apomorphine significantly reduced UPDRS scores for rigidity and akinesia. In only one patient was tremor reduced by the dopamine agonist but not by the anticholinergic. We found that anticholinergic and dopaminergic agents are both effective in reducing tremor in IPD, and there was no evidence for a selective anticholinergic responsiveness of parkinsonian tremor. Akinesia and rigidity, on the other hand, were not improved by biperiden. We therefore conclude that dopaminergic substances are as effective as anticholinergics in patients with parkinsonian tremor and additionally improve other parkinsonian signs.
Url:
DOI: 10.1002/1531-8257(199903)14:2<252::AID-MDS1009>3.0.CO;2-N
Affiliations:
- Allemagne, Autriche, Royaume-Uni
- Angleterre, Berlin, Grand Londres, Tyrol (Land)
- Berlin, Innsbruck, Londres
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></author><author><name sortKey="Scholz, Udo" sort="Scholz, Udo" uniqKey="Scholz U" first="Udo" last="Scholz">Udo Scholz</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CBBE34B5ED3DB8E6389E3363387F8E75358A3EE0</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199903)14:2<252::AID-MDS1009>3.0.CO;2-N</idno><idno type="url">https://api.istex.fr/document/CBBE34B5ED3DB8E6389E3363387F8E75358A3EE0/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002094</idno><idno type="wicri:Area/Main/Curation">001D93</idno><idno type="wicri:Area/Main/Exploration">001D43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges</title><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurology, Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Virchow‐Klinikum der Humboldt‐Universität zu Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Scholz, Udo" sort="Scholz, Udo" uniqKey="Scholz U" first="Udo" last="Scholz">Udo Scholz</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Virchow‐Klinikum der Humboldt‐Universität zu Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Universitätsklinik für Neurologie, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-03">1999-03</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="252">252</biblScope><biblScope unit="page" to="255">255</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CBBE34B5ED3DB8E6389E3363387F8E75358A3EE0</idno><idno type="DOI">10.1002/1531-8257(199903)14:2<252::AID-MDS1009>3.0.CO;2-N</idno><idno type="ArticleID">MDS1009</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticholinergics</term><term>Apomorphine</term><term>Biperiden</term><term>Parkinson's disease</term><term>Tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated the effect of an anticholinergic (biperiden) and a dopamine agonist (apomorphine) on tremor, rigidity, and akinesia in patients with idiopathic Parkinson's disease. In a standardized, crossover study design 17 patients received single‐dose challenges of 5 mg biperiden intravenously and a previously determined dose of apomorphine subcutaneously on 2 consecutive days. Resting (RT), postural (PT), and action tremor (AT) were assessed using spectral analysis of accelerometer data, and Unified Parkinson's Disease Rating Scale (UPDRS) scores for rigidity and akinesia were determined before and after administration of the study drug. Both single‐dose challenges significantly reduced the amplitude of RT, PT, and AT, but only apomorphine significantly reduced UPDRS scores for rigidity and akinesia. In only one patient was tremor reduced by the dopamine agonist but not by the anticholinergic. We found that anticholinergic and dopaminergic agents are both effective in reducing tremor in IPD, and there was no evidence for a selective anticholinergic responsiveness of parkinsonian tremor. Akinesia and rigidity, on the other hand, were not improved by biperiden. We therefore conclude that dopaminergic substances are as effective as anticholinergics in patients with parkinsonian tremor and additionally improve other parkinsonian signs.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Berlin</li><li>Grand Londres</li><li>Tyrol (Land)</li></region><settlement><li>Berlin</li><li>Innsbruck</li><li>Londres</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name></region></country><country name="Allemagne"><region name="Berlin"><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></region><name sortKey="Scholz, Udo" sort="Scholz, Udo" uniqKey="Scholz U" first="Udo" last="Scholz">Udo Scholz</name></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CBBE34B5ED3DB8E6389E3363387F8E75358A3EE0
|texte= Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges
}}
| This area was generated with Dilib version V0.6.23. |  |